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THE discovery of two isoforms of the cyclooxygenase
enzyme, COX-1 and COX-2, and the development of
COX-2-specific inhibitors as anti-inflammatories and
analgesics have offered great promise that the thera-
peutic benefits of NSAIDs could be optimized through
inhibition of COX-2, while minimizing their adverse
side effect profile associated with inhibition of COX-1.
While  COX-2 specific  inhibitors have proven to  be
efficacious in a variety of inflammatory conditions,
exposure of large numbers of patients to these drugs
in  postmarketing  studies  have  uncovered potential
safety concerns that raise questions about the bene-
fit/risk ratio of COX-2-specific NSAIDs compared to
conventional NSAIDs. This article reviews the efficacy
and safety profiles of COX-2-specific inhibitors, com-
paring them with conventional NSDAIDs.
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Introduction
In 1971, Sir John Vane discovered that aspirin worked
by  inhibiting  the  action  of  cyclooxygenase  (COX)
(also termed prostaglandin endoperoxide synthetase)
in  synthesizing  prostaglandins.1 That  discovery
spurred the synthesis of several additional drugs that
also inhibited cyclooxygenase, and had anti-inflamma-
tory properties. To distinguish these drugs (including
aspirin and other salicylates) from anti-inflammatory
glucocorticoids, they were collectively termed non-
steroidal anti-inflammatory drugs (NSAIDs).
In  the  late  1980s  and  early  1990s,  a  series  of
discoveries were made that led to the identification of
two COX enzymes: COX-1, which is a constitutively
expressed  isoform  involved  in  physiologic  main-
tenance  functions;  and  COX-2,  which  is  predom-
inantly  synthesized  in  response  to  inflammatory
stimuli.2–4 This  recognition  quickly  resulted  in  the
synthesis of compounds that specifically inhibit COX-
2  while  sparing  COX-1,  with  the  hopes  that  such
compounds would be  at least as efficacious as and
safer than NSAIDs, which inhibited both COX-1 and
COX-2.
NSAIDs can be placed into three categories with
respect to inhibition  of COX-1 and COX-2:  conven-
tional or non-selective NSAIDs, which either preferen-
tially  inhibit  COX-1  or inhibit  COX-1  and COX-2  at
about the  same plasma concentration; COX-2-selec-
tive NSAIDs, which preferentially inhibit COX-2, but
at higher therapeutic concentrations can also inhibit
COX-1;  and  COX-2-specific  NSAIDs,  which  even  at
higher therapeutic concentrations inhibit only COX-2
and  spare  COX-1.  While  NSAIDs  largely  share  the
same therapeutic properties, the adverse effect pro-
file of each NSAID depends in part on its behavior
with respect to COX-1 and COX-2 inhibition.
Biochemistry and pharmacology of
NSAIDs
Mechanism of action of NSAIDs
The  COX  enzyme  has  two  distinct  active  sites,
respectively  termed  the  cyclooxygenase  active  site
and the peroxidase active site. The cyclooxygenase
site cyclizes arachidonic acid and adds a hydroperoxy
group to carbon 15 to form prostaglandin G2 (PGG2).
The  separate  peroxidase  site  of  the  same  COX
molecule then reduces this hydroperoxy group to the
hydroxy  group  to  form  PGH2.  NSAIDs  inhibit  the
cyclooxygenase active site of COX, but have no effect
on the peroxidase active site, a finding confirmed by
recent X-ray crystallographic evidence of COX incu-
bated with selected NSAIDs.5,6
The identification of two COX isoenzymes, COX-1
and  COX-2,  prompted  numerous  investigations  to
define  the  structure–function  relationship  of  each
isoform.  COX-1  and  COX-2  are  encoded  by  two
different genes. The amino acid sequences of human
COX-1 and human COX-2 are 63% identical and 78%
similar.  The  cyclooxygenase  active  sites  (and  the
NSAID binding  sites)  of  human  COX-1  and  human
COX-2 are highly conserved, differing by only a single
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Mediators of Inflammation, 11, 275–286 (2002)amino acid. Residue 523 is an isoleucine in COX-1 and
a  valine  in  COX-2  (Fig.  1).  The  absence  of  the
additional  methyl  group  on  the  valine  in  COX-2
compared with the isoleucine in COX-1 produces a
side pocket as part of the NSAID binding site of COX-
2, which is not present in the NSAID binding site of
COX-1, and increases the overall size of the binding
site.7 Conventional  non-selective  NSAIDs  fit  the
NSAID binding sites of both COX-1 and COX-2, and
act  as  reversible  competitive  inhibitors  of  both
enzymes. Aspirin acetylates the active cyclooxygenase
site,  forming  a  covalent bond,  and  thus  acts as an
irreversible inhibitor of both COX-1 and COX-2.
COX-2-specific  inhibitors  such  as  celecoxib  and
rofecoxib are larger than conventional NSAIDs. These
specific inhibitors have a conformation that precludes
them from readily fitting into the NSAID binding site
of COX-1 but allows them to easily fit into the side
pocket  of  the  NSAID  binding  site  of  COX-2. This
difference in  part explains  the COX-2  selectivity of
these newer  NSAIDs. In  addition, however,  kinetic
studies have established two distinct mechanisms by
which  COX-2-specific  NSAIDs  inhibit  COX-1  and
COX-2. Specific COX-2 inhibitors such as celecoxib
and  rofecoxib  show  a  time-dependent  irreversible
inhibition  of  COX-2,  whereby  the  drug  appears to
alter the active cyclooxygenase site following  bind-
ing. At very high doses, however,  these same com-
pounds act as time-independent reversible inhibitors
of  COX-1,  with  the  degree  of  inhibition  of  COX-1
dependent on arachidonic acid concentration, drug
concentration, and affinity for the active site.8–10
Tissue distribution of COX-1 and COX-2
COX-1 is constitutively expressed in most tissues, and
appears  to  act  in  a  homeostatic  or  cytoprotective
manner. The tissues  expressing  COX-1  that demon-
strate the most clinically relevant NSAID effects are
the  gastrointestinal  (GI)  mucosa,  the  kidneys,  and
platelets. (While the GI mucosa and the kidney can
also express COX-2, platelets express only COX-1 and
cannot be  induced  to express  COX-2.)  In  contrast,
COX-2 is absent from most tissues (it does appear to
be constitutively expressed in brain, testes, and the
kidney11),  but  can  be  induced  in  most  tissues  by
cytokines, endotoxin, tumor promoters, growth fac-
tors, and gonadotropins.2,3,12,13 After induction, COX-
2  can  be  found  in  multiple  cell  types,  including
macrophages, monocytes, synoviocytes, ovarian fol-
licles,  colonic  adenomas and  cancer  cells,  vascular
smooth  muscle  cells,  bone,  and  amnion,  and  in
increased amounts in the brain, spinal cord, and the
kidney.
COX-1 and COX-2 have identical enzymatic actions,
and synthesize PGH2. Depending on the tissue where
it is synthesized, PGH2 can be converted to prosta-
glandins PGD2, PGE2, PGF2a, and PGI2 (prostacyclin),
and  to  thromboxane.  In  turn,  the  physiologic  or
pathophysiologic actions of each of these prostanoids
are dependent on the microenvironment where it is
made. PGE2 synthesized by  the  cells  of  the gastric
mucosa  serves  a  cytoprotective  role,  while  PGE2
synthesized by  the  synovial  lining  of  a  rheumatoid
arthritis  joint  is  pro-inflammatory.  Thromboxane
A2(TxA2) synthesized by COX-1 in platelets promotes
their aggregation. PGI2 is synthesized at least in part
by COX-2 within arterial walls, inhibits the aggrega-
tion of platelets, is a potent vasodilator, and opposes
the actions of TxA2. In addition, prostaglandins can
act in an autocrine, paracrine, or endocrine manner.
Inhibition  by  NSAIDs  of  COX-1-synthesized  prosta-
glandins or thromboxanes appears to be responsible
for many of the common adverse effects of NSAIDs,
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FIG. 1. Differences between the cyclooxygenase active sites of COX-1 and COX-2. The isoleucine at position 523 (Iso 523) in
COX-1 is replaced by a valine in COX-2. This substitution creates a side pocket of the active binding site of COX-2, not present
in COX-1, and a somewhat wider binding site in COX-2.such as stomach ulceration, renal effects, and inhibi-
tion of platelet aggregation. When prostaglandins are
synthesized  by  induced  COX-2  at  particular  tissue
sites,  their  pro-inflammatory  actions  can  result  in
erythema, edema, tenderness, pain and fever. Inhibi-
tion by COX-2-specific NSAIDs of COX-2-synthesized
prostaglandins appears to be responsible for at least
some adverse renal effects, and possibly some adverse
cardiovascular effects13 (Fig. 2).
Chemical properties of COX-2 specific NSAIDs
COX-2-specific  NSAIDs are weak organic acids, and
lipophilic. Thus, the lower the pH, the greater is their
lipophilicity. This combination of chemical properties
allows the COX-2-specific NSAIDs (as well as conven-
tional NSAIDs) to cross lipid  membranes, including
the blood–brain barrier, and to accumulate in acidic
tissues such as the stomach, renal medulla, and sites
of inflammation.14
COX-2 selectivity
The  COX-2  selectivity of NSAIDs is  defined by  the
COX-1/COX-2 ratio. The larger this ratio, the greater
the  selectivity  of  the  compound  is  for  COX-2.
However, this ratio can vary remarkably, depending
on which of the different in vitro and in vivo assays
is  used  to  generate  the  ratio.  Furthermore,  it  is
important to realize that, especially for the in vitro
assays, the assay conditions may vary from laboratory
to laboratory, and thus the ratio for a given drug can
vary  over  a  wide  numerical  range  depending  on
which laboratory is reporting the result.
The in vitro assay that determines the concentra-
tions  required  to  inhibit  50%  of  the  activities  (the
IC50 values)  of  purified  recombinant human  COX-1
and  purified  recombinant  human  COX-2,  respec-
tively, is the most direct method for determining the
specificity  of  a  given  compound  for  COX-2.  How-
ever, because this assay does not take into account
factors  that  occur  in  vivo,  such  as  intracellular
locations of COX-1 and COX-2, and potential differ-
ences in local intracellular drug concentrations, the
COX-1/COX-2 ratio generated by this assay does not
reflect the clinical situation. A second in vitro assay,
the  whole  blood  assay,  incorporates  some  of  the
factors already noted, and examines the IC50 values
needed to  inhibit  the  synthesis of thromboxane (a
purely  COX-1-initiated  event)  synthesized  by  plate-
lets  during  aggregation,  and  of  PGE2 elaborated
following  lipopolysaccharide  stimulation  of  mono-
cytes (a purely COX-2-mediated event).15 The results
of  this  assay,  however,  can  be  affected  by  the
particular assay conditions used and, thus, again do
not  adequately  reflect  the  clinical  situation.  The
most  relevant  COX-1/COX-2  ratios  are  generated
using in vivo assays. Such assays were developed in
the  rat,  and  were  used  to  determine  the  dose
required  to  inhibit  50%  of  the  activities  (the  ED50
value)  of  COX-1  (as  determined  by  synthesis  of
gastric prostaglandins) and of COX-2 (as determined
COX-2 inhibitors
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FIG. 2. The tissues where COX-1 and COX-2 are constitutively expressed and COX-2 is inducibly expressed, and where NSAIDs
may exhibit clinical effects. The inhibitory actions of non-selective NSAIDs on COX-1 and COX-2, and the inhibitory actions of
COX-2-specific NSAIDs on constitutive and inducible COX-2, are schematically illustrated.by  synthesis  of  prostaglandins induced in  response
to carrageenan injected into an air pouch),  respec-
tively.16 The  COX-1/COX-2  ratios  for  select  NSAIDs
and  COX-2  inhibitors  as  determined  by  various
assays  are  presented  in  Table  1.17–20 Ultimately,
however,  the  most  meaningful  classification  of  a
NSAID  with  respect  to  COX-2  selectivity  is  that
based  on  clinical  criteria.  On  this  basis,  ‘COX-
2-specific’  inhibitors  inhibit  only  COX-2-mediated
events, and not COX-1-mediated events even at high
therapeutic  doses.  Clinical  data  suggest  that  cel-
ecoxib,  rofecoxib,  valdecoxib,  and  etoricoxib  are
‘COX-2-specific’.  ‘COX-2-selective’  or  ‘COX-2-prefer-
ential’  inhibitors  inhibit  COX-2-mediated  events  at
low  therapeutic  doses,  but  inhibit  COX-1-mediated
events at higher clinically therapeutic doses. Clinical
data suggest that meloxicam, nabumatone, and eto-
dolac  are  ‘COX-2-selective’.  ‘COX-2-non-selective’
inhibitors  at  clinically  relevant  therapeutic  doses
inhibit  COX-1-mediated  events  preferentially  or
inhibit  COX-1-  and  COX-2-mediated  events  approx-
imately  equally.  Most conventional NSAIDs fall  into
this category.
Clinical experience: efficacy of COX
inhibitors
Roles of COX-1 and COX-2 in analgesic and
anti-pyretic efficacy of NSAIDs
Local tissue injury and inflammatory diseases such as
rheumatoid arthritis and osteoarthritis are associated
with increased prostaglandin synthesis, which sensi-
tizes  pain  receptors  to  lower  levels  of  stimuli.21
NSAIDs  exert  their  analgesic  effects  by  interfering
with the hyperalgesia induced by local synthesis of
prostaglandins at the site of injury or inflammation. In
addition, prostaglandins are thought to act centrally
to  facilitate  transmission  of  pain  responses,22,  and
NSAIDs can cross the blood–brain barrier to act at
these central sites.23 Studies in animal models have
implicated both COX-1 and COX-2 in the release of
centrally and peripherally acting prostaglandins, and
have  suggested  that  inhibition  of  both  COX-1  and
COX-2 may contribute to the spinal analgesic and anti-
hyperalgesic  actions  of  NSAIDs.24,25 However,  the
relative roles of the two COX isoforms have not yet
been  completely  defined.  COX-2  expression  is
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Table 1. COX-1/COX-2 ratios
a for selected NSAIDS by various assays
Drug Human recombinant
enzymes
b
(COX-1 IC50/COX-2 IC50)
Whole blood
assay
c
(COX-1 IC50/COX-2 IC50)
In vivo
d
(COX-1 ED50/COX-2 ED50)
Non-selective (conventional) NSAID
5
Flurbiprofen –
f 0.097 –
Ketoprofen – 0.123 –
Tolmetin – 0.254 –
Aspirin – 0.321 –
Oxaprozen – 0.397 –
Naproxen 0.136 0.559 5
Indomethacin 0.1 0.562 2
Ibuprofen 0.215 0.592 0.1
Ketorolac – 0.610 –
Piroxicam 1.026 1.266 0.1
Diclofenac 3 20 5
Mefenamic acid – 12.5 –
Selective COX-2 inhibitors
6-MNA – 1.563 0.01
Etodolac > 1.852 9.09 0.2
Meloxicam 0.765 11.1 0.5
Nimesulide – 25 –
Specific COX-2 inhibitors
Celecoxib 375 7.6–9.09 > 33
Rofecoxib 1000
g 20–35 –
Valdecoxib 35,000 30
h –
Etoricoxib – 106
8 –
a Expressed as the ratio of the 50% inhibitory concentration or inhibitory dose for COX-1 to the 50% inhibitory concentration or inhibitory dose
for COX-2. Ratios < 1 indicate preferential inhibition of COX-1, and ratios > 1 indicate preferential inhibition of COX-2. The larger the ratio, the
more selective the drug. These ratios may vary by 10-fold depending on assay conditions.
b Data from preference 18.
c Data from preference 19.
d Data from preference 3.
e Designations  of  COX-2-non-selective,  COX-2-selective,  and  COX-2-specific  are  based  on  the  presence  or  absence  of  inhibition  of  COX-
1-mediated events at therapeutic levels of NSAID that inhibit COX-2-mediated events in vivo.
f –, information not available.
g Data from reference 9.
h Data from reference 20.increased locally at sites of injury and inflammation,26
as well as in spinal cord neurons following peripheral
inflammation.27 At doses that maintain selectivity for
COX-2, COX-2 inhibitors have shown equal analgesic
efficacy to non-selective NSAIDs for treatment of pain
associated  with  dental  surgery,  osteoarthritis,  and
dysmenorrhea.26,28,29
Exogenous pyrogens (e.g. bacterial endotoxin and
viruses)  induce  fever  via  a  cascade  of  molecular
interactions that include induction of the synthesis and
release of the endogenous pyrogenic cytokines inter-
leukin  (IL)-1  and  IL-6,  which  in  turn  induce  COX-
mediated prostaglandin synthesis in the central nerv-
ous  system.30 Non-selective  NSAIDs  are  effective
anti-pyretics in both animal models and humans by
inhibiting synthesis of fever-mediating prostaglandins.
Recent  biochemical  and  clinical  data  implicate  the
COX-2 isoform in the pathogenesis of fever in humans.
COX-2 expression is induced in the brain vasculature,
with  temporal  correlation  to  the  development  of
fever,31 and COX-2 knock-out mice fail to develop fever
in response to inflammatory stimuli.32 COX-2-specific
inhibitors reduce naturally occurring fever in humans
with efficacy similar to non-selective NSAIDs.33
Roles of COX-1 and COX-2 in
anti-inflammatory efficacy of NSAIDs
NSAIDs are widely prescribed for and provide effec-
tive treatment of a variety of inflammatory conditions,
including  osteoarthritis, rheumatoid  arthritis,  acute
gout,  acute bursitis,  and  spondylarthropathies. Spe-
cific COX-2 inhibitors are indicated for osteoarthritis,
rheumatoid  arthritis,  and  management  of  acute
pain.34,35 Substantial individual variability exists with
respect to the pharmacology and pharmacokinetics of
NSAIDs and specific COX-2 inhibitors, necessitating
individualization  of  treatment  to  the  patient  and
disease.  Furthermore,  the  optimum  dosage  varies
from  one disorder to the next.  Moderate doses are
often sufficient to treat osteoarthritis, whereas rheu-
matoid arthritis or other types of chronic inflamma-
tory arthritis usually  require sustained therapy with
maximum tolerated doses.
Experimental  evidence  suggests  that  local  PGE2
production is central to the pathogenesis of inflamma-
tion.26 Results obtained in animal models of inflamma-
tory arthritis associate increased expression of COX-2
with increased prostaglandin production in inflamed
joint tissues.36 COX-2 is greatly upregulated at sites of
inflammation in humans; induction of COX-2 expres-
sion  has  been  observed  in  cartilage  from  osteoar-
thritis patients and synovial tissue from rheumatoid
arthritis  patients.37,38 COX-2  expression  in  primary
cultures  of  human  synovial  tissue  or  inflammatory
cells (e.g. monocytes) is induced by the pro-inflamma-
tory cytokines IL-1 and tumor necrosis factor-a, while
the  anti-inflammatory  cytokines  IL-4  and  IL-13  and
immunosuppressive glucocorticoids decrease COX-2
levels.39 Clinical  trials  comparing  COX-2-specific
inhibitors with non-selective NSAIDs in osteoarthritis
and rheumatoid arthritis have shown that the same
therapeutic endpoints are reached with both types of
drugs,  suggesting  that COX-2-specific  inhibitors are
equally efficacious as non-selective NSAIDs.40,41
Roles of COX-1 and COX-2 in efficacy of
NSAIDs in cancer
Epidemiological  data  have  shown  an  association
between regular use of aspirin or other NSAIDs and
decreased incidence of and mortality from colorectal
cancer.42–44 Regular aspirin use has been shown to
decrease both colorectal cancer incidence and mortal-
ity by approximately 40%.43,44 Sulindac administration
has been shown to reduce the size and number of
adenomas  in  patients  with  familial  adenomatous
polyposis  (FAP),  a  hereditary  disease  that  leads  to
colorectal cancer by the fifth decade of life in virtually
all patients.45 COX-2 has been implicated in carcinoge-
nesis in animal models of the disease,46,47 and COX-2
has been shown to be highly upregulated in human
colorectal adenomas and adenocarcinomas compared
with normal mucosa,48 suggesting a role for COX-2 in
transformation.  However,  no  data  are  yet  available
demonstrating an association between NSAID admin-
istration and decrease in cancer incidence in patients
with FAP. The COX-2-specific inhibitor celecoxib has
been  shown  to  significantly  reduce  the  size  and
number of colorectal polyps in patients with FAP, and
has been approved by the Food and Drug Administra-
tion as an adjunct to usual care for patients with FAP.49
Increased prostaglandin synthesis via COX-2 upregula-
tion in  bladder cancer,50 and other GI cancers,51,52
suggests that COX-2-specific inhibitors may be useful in
the prevention or treatment of these cancers as well.
Roles of COX-1 and COX-2 in effects of NSAIDs
in Alzheimer’s disease
Non-selective  NSAIDs  have  been  evaluated  for  the
treatment and prevention of Alzheimer’s disease with
promising results. Studies have shown slower disease
progression  and  cognitive  decline  in  NSAID-treated
patients  compared  with  matched  control  popula-
tions.53–55 Longitudinal  studies  have  demonstrated
that the relative risk of developing Alzheimer’s disease
is  decreased in  patients  using  NSAIDs and  is  asso-
ciated with the duration of use.55–57 Animal studies
have shown that COX-2 is localized during develop-
ment to areas of  the brain  related to memory (e.g.
hippocampus, cortex),58, and that COX-2 appears to
be involved in postsynaptic signaling of cortical and
other excitatory neurons in the adult brain.59 COX-2
expression  in  the  brain  can  be  upregulated  by  a
variety of stressful stimuli, including seizure.58 Other
COX-2 inhibitors
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activated  microglia  in  cerebral  inflammatory  pro-
cesses thought to parallel the inflammatory cascade
of events in the human brain that lead to deposition of
b-amyloid protein, the hallmark histologic manifesta-
tion  of  Alzheimer’s  disease.60 These  clinical  and
biochemical data suggest a potential for COX-2-spe-
cific NSAIDs in the future treatment and prevention of
Alzheimer’s disease.
Clinical experience: toxicities associated
with COX inhibition
Although  inhibition  of  both  COX-1  and  COX-2  is
generally well tolerated, it is associated with a wide
spectrum of  potential clinical toxicities. In general,
adverse  events  tend  to  be  dose  related.61 Many
adverse  events  are  attributed  to  inhibition  of  the
constitutively expressed COX-1 enzyme, and some of
these appear to be significantly reduced through the
use  of  COX-2-specific  inhibitors.  Other  of  these
adverse events, however, are not reduced by the use
of COX-2-specific inhibitors. Moreover, whether COX-
2-specific inhibitors cause their own set of adverse
events is emerging as an area of controversy.
COX-1 and COX-2 inhibition in GI toxicity
The chief clinical limitation of non-selective NSAIDs is
undoubtedly their toxic effect on the upper GI tract,
including ulceration, bleeding, obstruction, and per-
foration. Non-selective NSAIDs are thought to exert
both  a  direct  toxic  effect  on  the  gastroduodenal
mucosa as well as an indirect effect via inhibition of
COX-1-induced cytoprotective prostaglandins. Prosta-
noids PGE2 and PGI2, synthesized in the GI mucosa,
protect  the  mucosa  and  limit  gastric  acid  output.
Central  mucosal  defense  mechanisms  are  compro-
mised  by  the  decreased  prostaglandin  production
caused by chronic NSAID-induced COX-1 inhibition,
leading to ulceration and bleeding diathesis. NSAID-
induced inhibition of COX-1 leads to increased gastric
acid production, decreased production of bicarbon-
ate, and a decreased rate of cellular proliferation of
the gastric mucosa, all of which impair the normal
protective mechanisms of the stomach. NSAIDs cause
or  aggravate  GI  bleeding,  both  by  increasing  acid
production in the stomach and by decreasing platelet
adhesiveness (see later).62,63
Post-marketing surveillance and endoscopic studies
have confirmed that the incidence of gastroduodenal
mucosal injury is reduced with the use of nabumatone,
etodolac,  and  meloxicam,  in  part  due  to  their
selectivity for COX-2 inhibition, with a minimal effect
on  COX-1,  at  least  at  lower  therapeutic  doses.64,65
Specific COX-2 inhibitors have also been shown by
endoscopy to markedly reduce injury to the gastro-
dudenal mucosa. Two of these compounds, celecoxib
and  rofecoxib,  have  been  extensively  studied  by
endoscopy and appear to maintain their selectivity for
COX-2 at doses substantially higher than those required
to affect inflammation. In these studies, the incidence
of endoscopic gastroduodenal ulcers attributable to
specific COX-2 inhibitors is not significantly different
from that found with placebo,66,67 and is dramatically
less than that seen with conventional NSAIDs.
However, whether a difference exists between non-
selective NSAID inhibition and COX-2-specific inhibi-
tion in protection from clinically significant GI events
is  not  at  all  as  clear.  The  US  Food  and  Drug
Administration estimates that clinically significant GI
events  resulting  from  ulceration,  including  perfora-
tion,  obstruction,  and  bleeding,  occur  in  approx-
imately 1–2% of patients using non-selective NSAIDs
for 3 months and in approximately 2–5% of patients
using them for 1 year. Two to four per cent of patients
on  long-term  therapy  are  hospitalized  each  year
because  of  GI  complications.68 Prior  peptic  ulcer
disease, advanced age, high NSAID doses or therapy
with multiple NSAIDs, and concomitant therapy with
either  corticosteroids or  anticoagulants all  increase
the risk of a GI complication in patients taking non-
selective  NSAIDs  chronically. There  are  some  data
indicating that comorbidities such as cardiovascular
disease and rheumatoid arthritis increase the risk of
NSAID-induced  gastrointestibnal  complications.  It
was hoped that the use of COX-2-specific inhibitors
would decrease this incidence.
Two  large  trials  have  been  conducted. The  first,
the CLASS trial,69,70 compared celebrex with diclofe-
nac and ibuprofen in osteoarthritis and rheumatoid
arthritis patients. Patients were allowed to take up
to  325mg  of  aspirin  per  day  for  cardiovascular
protection.  The  12–month  results  of  the  trial
showed  no  statistically  benefit  of  celecoxib  over
diclofenac in protection from clinically significant GI
events in patients overall, or in either the subset of
patients  who  took  aspirin  or  who  did  not  take
aspirin. Furthermore, there was no statistical benefit
of  celecoxib  over  ibuprofen  in  protection  from
clinically  significant  GI  events  in  patients  overall.
Celecoxib  did  appear  to  have  a  statistically  sig-
nificant  benefit  over  ibuprofen  in  patients  not  on
aspirin,  but,  paradoxically,  ibuprofen  had  a  statis-
tically  significant  benefit  over celecoxib in  patients
who were taking aspirin. A possible explanation for
this paradoxical finding has recently emerged71 (see
later).  In  the  second  trial,  the VIGOR  trial,72 rofe-
coxib was compared with naproxen in rheumatoid
arthritis patients only.  No aspirin use was allowed.
Rofecoxib  demonstrated  a  statistically  significant
benefit over naproxen with respect to significant GI
events,  but  there  was  an  unexpected  statistically
significant  increase  in  cardiovascular  events  in
patients  on  rofecoxib  compared  with  patients  on
naproxen (see later).
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cardiovascular effects
Platelets  have  only  the  COX-1  isoform  of  cycloox-
ygenase,  and  use  COX-1-derived  PGH2 to  generate
TxA2, a key autocrine stimulator of platelet aggrega-
tion and vasoconstriction. Non-selective NSAIDs, by
inhibiting  COX-1  and  thus  platelet TxA2 synthesis,
inhibit platelet function and can exacerbate bleeding
in  patients  who  are  otherwise  at  risk.73 Because
platelets lack mitochondria and are unable to synthe-
size  additional  cyclooxygenase,  acetylation  of  this
enzyme by aspirin irreversibly inhibits platelet activa-
tion in  response to  a  variety of  stimuli. This  effect
persists for 10–12 days until the acetylated platelets
are replaced by newly produced platelets that have
not been exposed to aspirin.74 This property has led
to the use of aspirin in doses as low as 80mg daily in
cardiovascular prophylaxis to prevent platelet aggre-
gation  and  emboli  in  patients  with  a  history  of  a
myocardial  infarction,  angina,  cerebrovascular  acci-
dent,  transient  ischemic  attack,  angioplasty,  and
coronary bypass, but it also increases the risk of GI
and  other  bleeding  events.  In  contrast  to  aspirin,
cyclooxygenase  inhibition  by  other  non-selective
NSAIDs is reversible, and their platelet effects corre-
late roughly with the half-life of the drug, lasting only
as long as the drug is present. COX-2-specific NSAIDs
completely  spare  platelet  function  at  therapeutic
doses,75 and do not interfere with the effect of aspirin
on  platelets  when  co-administered  with  aspirin.71
However, recent data suggest that ibuprofen71 (and
possibly  other conventional NSAIDs),  when  admin-
istered concurrently with aspirin, blocks aspirin from
reaching the COX-1 binding site, thereby diminishing
the effect of aspirin on inhibition of TxA2 production,
and abrogating the effect of aspirin on inhibition of
platelet aggregation. Extrapolation of this observation
to  COX-1  in  the  GI  mucosa  may  explain  the  para-
doxical effect of ibuprofen on lowering the ulceration
rate in the CLASS study.69,70
Aspirin and other non-selective NSAIDs do not cause
major bleeding events in the vast majority of patients
who use them. The clinical manifestations induced by
exposure to non-selective NSAIDs are mild,  in  part
because TxA2 is  only  one  of  several  mediators  of
platelet activation.  Thrombin and other strong platelet
agonists can induce platelet aggregation even in the
presence of concomitant exposure to  non-selective
NSAIDs.76 However, in patients with impaired hemos-
tasis,  the  decreases in  platelet TxA2 resulting  from
COX-1 inhibition can pose significant clinical risk.
GI  bleeding  is  the  most  common  spontaneous
bleeding event associated with the use of aspirin and
non-selective NSAIDs. Other clinical  bleeding  prob-
lems associated with the use of non-selective NSAIDs
are increased risk of intracerebral hemorrhage, fetal
and neonatal bleeding abnormalities caused by mater-
nal ingestion of NSAIDs in the peripartum period, and
increased  risk  of  post-operative  bleeding  following
cardiac and other surgeries in patients taking aspirin
and  other  NSAIDs  preoperatively.77 COX-2-specific
NSAIDs, which have been shown to preserve platelet
function at therapeutic doses, obviate these bleeding
problems,  and  their  use  should  not  need  to  be
restricted perioperatively.75
However, the preservation of platelet function by
COX-2-specific NSAIDs may pose an increased risk for
cardiovascular  events  in  patients  who  use  these
drugs,  and  are  already  at  risk  for  such  events. As
already noted, the VIGOR trial72 compared rofecoxib
with naproxen in rheumatoid arthritis patients, who
were not permitted to take aspirin. While cardiovas-
cular events were not a primary endpoint of the trial,
they  were  monitored  and  reported.  There  was  a
statistically  significant  increase  in  the  number  of
myocardial infarctions in the patients in the rofecoxib
arm  of  the  trial  compared  with  patients  in  the
naproxen arm of the trial. While patients at risk for
cardiovascular  events  should  have  been  excluded
from the trial, a retrospective analysis indicated that a
small subset of patients in the trial met the criteria of
the Food and Drug Administration for use of aspirin
for secondary cardiovascular prophylaxis,  but  were
not taking aspirin. These patients, representing 4% of
the  study  population,  accounted  for  38%  of  myo-
cardial  infarctions  that  occurred  during  the  trial.
There are three possible explanations for the finding.
First,  it may  be a statistical aberration because the
numbers  are  relatively  small;  second,  naproxen,
because of its non-selectivity and inhibition of COX-1,
may be protective against such cardiovascular events;
and  third,  rofecoxib  may  be  predisposing  to  such
events. In this third scenario, it has been hypothe-
sized  that  rofecoxib  is  inhibiting  COX-2-induced
synthesis of prostacyclin by the vasculature, prevent-
ing vasodilatation and antagonism of platelet aggrega-
tion,  thus  leaving  the  effects  of  COX-1-induced
platelet aggregation unopposed (see earlier). It should
also  be  noted  that  the VIGOR  trial  studied  solely
patients  with  rheumatoid  arthritis,  which  by  itself
may be a risk factor for cardiovascular events.78,79 No
such increase in cardiovascular events was seen in the
CLASS  trial,  which  studied  both  osteoarthritis  and
rheumatoid arthritis patients, and allowed aspirin use.
Indeed, a retrospective analysis of the CLASS trial data
comparing all  patients taking celecoxib  with those
taking ibuprofen and diclofenac, and comparing non-
aspirin  users  taking  celecoxib  with  those  taking
ibuprofen  and  diclofenac,  showed  no  statistically
significant  increase  in  the  incidences  of  serious
cardiovascular thromboembolic events between the
celecoxib  and  NSAID  comparators  (combined  or
individually) for all patients, as well as the subgroup
of patients not taking aspirin.80 The explanation for
the apparent discrepancy between the incidences of
COX-2 inhibitors
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ecoxib appears not due to the different comparators
used in the CLASS69.70 and VIGOR72 trials, and at this
time remains unclear.
COX-1 and COX-2 inhibition in renal toxicity
NSAIDs can adversely affect renal function by inhibit-
ing  synthesis  of  renal  prostaglandins  important  for
solute  homeostasis  and  for  maintenance  of  renal
blood  flow. The  most  significant  clinical  effects  of
NSAIDs are decreased sodium and potassium excre-
tion  and  decreased  renal  perfusion.  NSAIDs,  by
decreasing renal PGE2 levels, increase sodium reab-
sorption,  causing  weight  gain  and  edema  in  some
patients and, in rare cases, congestive heart failure. In
addition, the effect of NSAIDs on sodium retention
can decrease the response to anti-hypertensive drugs,
particularly  diuretics  and  angiotensin-converting
enzyme inhibitors. Inhibition of renal PGI2 by NSAIDs
decreases potassium excretion and can cause hyper-
kalemia,  usually  mild  but  in  rare  cases  sufficiently
severe  to  cause  cardiac  arrest.  Patients  at  risk  for
hyperkalemia (e.g. those with renal insufficiency or
on  potassium-sparing  diuretics)  should  have  their
serum  potassium  levels  monitored  at  the  onset  of
NSAID therapy,  since decreases in potassium secre-
tion can occur with the first dose of NSAID. While
maintenance of renal blood flow is independent of
renal prostaglandin synthesis in healthy individuals, in
clinical conditions where actual or circulating volume
is decreased (congestive heart failure, cirrhosis, and
renal insufficiency), renal perfusion is maintained by
renal  prostaglandins  responsible  for  vasodilatation.
NSAID administration to at-risk patients can result in
decreases in renal blood flow sufficient to cause acute
renal  failure.  Since  acute  renal  failure  can  develop
with the first dose of NSAID, careful monitoring of at-
risk patients is important. It is likely that the risk of
developing acute renal failure from NSAID therapy is
both dose and half-life related, with higher doses of
longer-acting NSAIDs associated with greater risk.81
Whether there are differences among NSAIDs for risk
of  acute renal failure  is unclear.  However,  a recent
study suggested that use of high dose aspirin is more
common in patients with chronic renal failure, then is
use of other NSAIDs82 Specific COX-2 inhibitors were
not examined in the present study. Nonetheless, both
non-selective and COX-2-specific  NSAIDs should be
used with appropriate monitoring in patients at risk
for NSAID-induced adverse renal events. Because both
COX-1 and COX-2 are expressed in the kidney,83 and
the relative physiological roles of each enzyme in the
kidney have not been fully elucidated, the extent to
which these adverse clinical effects might be obviated
by  COX-2-specific  inhibitors  has  not  been  fully
determined.  COX-2-specific  inhibitors  have  been
shown  to  inhibit  some  renal  prostaglandins,84 and
cause edema in 2–4% of patients in controlled clinical
trials,34,35 indicating that both non-selective and COX-
2-specific  inhibitors  may  have  similar  effects  on
sodium  homeostasis.85 However,  there  has  been  at
least one report suggesting that celecoxib results in a
lower  incidence  of  hypertension  and  edema  than
rofecoxib.86 This decreased incidence may be related
to the shorter half-life of celecoxib than of rofecoxib
(11h  versus  17h),  potentially  allowing  periodic
synthesis of renal prostaglandins that help maintain
renal function. It is also possible that the decreased
incidence of hypertension observed with celecoxib in
this study may be attributable to the blood pressure
being monitored only once a day just prior to dosing,
when drug plasma levels are at their nadir at steady
state, rather than at several times during the dosing
period. Further studies will be necessary to discern
whether  differences  exist  between  COX-2-specific
inhibitors with respect to renal effects.
COX-1 and COX-2 inhibition in hepatic toxicity
Hepatic toxicity has been reported with virtually all
NSAIDs  in  current  use.  Most  of  this  toxicity  is
clinically  mild  and  seems  to  be  unrelated  to  the
inhibition of COX. Reversible hepatocellular toxicity,
characterized  by  elevation  of  aminotransaminases,
has been observed in up to 15% of patients treated
with  NSAIDs.87 High  anti-inflammatory  doses  of
aspirin may cause this effect in up to 50% of patients,
and  even  more  frequently  in  patients  with  Still’s
disease  and  systemic  lupus  erythematosis  (SLE).
Transaminase elevations can occur at any time after
initiation of treatment, and usually revert to normal
with  dosage  adjustment  or  discontinuation  of  the
drug. In rare cases, NSAIDs may induce more severe
hepatic  dysfunction,  causing  elevated  bilirubin  or
prolonged prothrombin times, in which case the drug
must be discontinued.
Clinically significant events reflecting NSAID hep-
atotoxicity  are  uncommon.  It  has  been  estimated
from case–control studies that NSAID therapy increa-
ses the risk of hospitalization for acute symptomatic
hepatitis by approximately two-fold.88 Hepatocellular
cholestasis and granulomatous hepatitis induced by
phenylbutazone may  be  fatal in  some patients. The
most  commonly  reported hepatotoxicity of  clinical
significance occurs with sulindac. This drug is asso-
ciated with a syndrome that appears to be allergic in
nature, characterized by fever, rash, eosinophilia, and
liver  enzyme  elevations.  The  hepatic  toxicities
observed with NSAIDs do  not seem  to result  from
inhibition  of  COX;  therefore,  they  would  not  be
expected to be  more or less likely with the use of
COX-2-specific  inhibitors.  COX-2-specific  inhibitors
have not been fully evaluated in patients with severe
hepatic disease and should therefore be used with the
same caution as the non-selective NSAIDs.
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Both COX isoforms are present in the central nervous
system, in neurons as well as vascular and glial cells.
NSAIDs have been  associated with  central  nervous
system  side  effects.  Salicylates  can  cause  dose-
dependent tinnitus and hearing loss, and overdoses
can  severely  affect  the  central  nervous  system,
culminating in  coma and death; overdoses of other
NSAIDs  are  much  less  toxic.  Occasionally,  some
patients experience severe headaches on initiation of
NSAID  therapy;  this  effect  may  be  more  common
with indomethacin than with other NSAIDs, and has
been  seen  with  both  specific  COX-2  inhibitors,
celecoxib and rofecoxib.34,35 Confusion may appear
in  elderly  patients  treated  with  indomethacin,
naproxen, or ibuprofen. Aseptic meningitis has occur-
red  rarely  in  patients  treated  with  NSAIDs,  most
commonly ibuprofen.61 It has been reported prima-
rily in patients who have an underlying autoimmune
disease,  such  as  SLE  or  mixed  connective  tissue
disease, and recurs with rechallenge using the same
medication, but not with alternative NSAIDs, indicat-
ing that this is an idiopathic response to an individual
drug not a mechanism-based effect.
COX-1 and COX-2 inhibition in cartilage and
bone
Studies using non-selective NSAIDs have shown that
these drugs may accelerate the process of cartilage
destruction  in  osteoarthritis,  largely  by  inhibiting
proteoglycan  biosynthesis  in  cartilage.89,90 Potent
inhibitors of prostaglandin synthesis, such as indom-
ethacin  and  aspirin,  have  been  shown  to  reduce
proteoglycan synthesis in cartilage and promote the
acceleration of joint space narrowing observed radi-
ologically  in  patients  with  osteoarthritis.89,90 Inter-
estingly,  indomethacin  is  one  of  several  NSAIDs
shown to lack collagenase inhibitory activity, and it
may be that the combined inhibition of proteoglycan
biosynthesis  and  lack  of  inhibition  of  collagenase
activity allow for acceleration of cartilage destruction
by indomethacin. Of note, the COX-2-selective inhib-
itor,  meloxicam,  shows  no  inhibitory  effects  on
proteoglycan biosynthesis, but  does inhibit  collage-
nase activity, so would be predicted to be cartilage
sparing;  however,  the effects of meloxicam on the
progression of joint changes in osteoarthritis have not
yet been definitively tested.91
The effects of NSAID therapy on bone proliferation
and remodeling are complex and often contradictory.
Prostaglandins can both stimulate collagen synthesis
and  bone  formation,  as  well  as  promote  bone
resorption.92,93 It  has  been  reported  that  NSAIDs
suppress bone repair and remodeling,94 and also slow
the  process  of  bone  loss  associated  with  some
inflammatory conditions.95 Studies on the effects of
non-selective NSAIDs in animal models of osteoporo-
sis  have  given  conflicting  results,  showing  both
protection against and acceleration of bone loss.96,97
COX-1  is  expressed  in  osteoarthritis  cartilage  and
appears to be important in the repair of both cartilage
and  bone.98 The  effects  of  COX-2  inhibitors  on
cartilage  and  bone  structure  have  recently  been
examined.  In  in  vitro systems,  celecoxib  added to
tissue cultures of osteoarthritic cartilage normalized
proteoglycan  turnover,99 and  rofecoxib  added  to
tissue cultures of osteoarthritic cartilage inhibited IL-
1-induced matrix metalloproteinase-1, matrix metal-
loproteinase-3,  and  nitric  oxide  production,  and
reversed  IL-1  inhibition  of  cartilage  synthesis,100
suggesting  that  specific  COX-2  inhibition  may  be
chondroprotective. However, in an in vivo drug test
chamber  model  in  rabbits,  rofecoxib  administered
orally  suppressed  bone  formation,101 raising  the
possibility that specific COX-2 inhibition could delay
fracture  healing.  Thus,  it  appears  that  the  net
observed effect of a particular NSAID on bone and
cartilage structure results from a complicated inter-
play  of  COX-1-  and COX-2-controlled prostaglandin-
mediated resorptive and formative processes.
Drug interactions of conventional and
COX-2-specific NSAIDs
While  individual  NSAIDs  vary  in  their  interactions
with other classes of drugs, many of these interactions
have  their  basis  in  the  mechanism  of  action  of
NSAIDs,  and  are  common  to  many,  if  not  all,
NSAIDs.85 Aspirin, in other than cardiovascular pro-
tective doses, should not be used together with other
NSAIDs, as the combinations increase the potential
for adverse effects common to this class. In addition,
ibuprofen (and possibly other conventional NSAIDs)
may  diminish  or  abrogate  the  cardiovascular  pro-
tective  effect  of  aspirin  when  the  two  drugs  are
administered concurrently.71 In contrast, COX-2-spe-
cific  inhibitors  do  not  abrogate  the  cardiovascular
protective  effects  of  aspirin.71 Aspirin  and  NSAIDs
may also share the same protein binding  sites, and
either  aspirin  can  displace  the  NSAID,  resulting  in
increased clearance and decreased plasma levels  of
the NSAID, or the NSAID can displace aspirin. Some
NSAIDs, including aspirin, can cause displacement of
other  drugs  from  their  protein  binding  sites,  so
caution needs to be used with patients on sulfony-
lurea  hypoglycemics,  phenytoin,  valproic  acid,  and
carbonic  anhydrase  inhibitors.  Some,  but  not  all,
NSAIDs can also displace warfarin. Even with NSAIDs
that do  not displace warfarin,  patients  on  warfarin
and  a  NSAID  need  to  have  their  protimes  and/or
International Normalized Ratios monitored. The inter-
ference  of  NSAIDs  with  synthesis  of  renal  prosta-
glandins can blunt the natriuretic effects of loop and
COX-2 inhibitors
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tensive  effects  of  angiotensin-converting  enzyme
inhibitors and b-blockers. Many, but not all, NSAIDs
can  cause  decreased renal  clearance and  increased
plasma levels of lithium, digoxin, cyclosporin A, and
methotrexate. Patients on these drugs together with
an NSAID should be monitored closely for toxicity.
Antacids may interfere with absorption and therefore
decrease  plasma  concentrations  of  some  NSAIDs.
Probenecid  may  decrease  renal  clearance  and
increase blood levels of some NSAIDs.
The COX-2-specific NSAIDs share most of the same
concerns regarding drug interactions. In addition, it is
known that celecoxib is metabolized by cytochrome
P450 2C9, so any inhibitor of this enzyme should be
used  with  caution  in  patients  on  celecoxib.  In
particular,  administration  of  fluconazole  at  200mg
per day resulted in a two-fold increase in the plasma
concentration  of  celecoxib.  In  contrast  to  most
NSAIDs, co-administration of  celecoxib  and  metho-
trexate  does  not  appear  to  increase  methotrexate
levels.  Rofecoxib  is  metabolized  primarily  by  cyto-
solic enzymes, and not by the P450 system. However,
co-administration of rifampin with rofecoxib results
in a 50% decrease in rofecoxib plasma concentrations,
primarily  through  induction by  rifampin  of general
hepatic metabolic activity.
Conclusions
NSAIDs are the most widely prescribed class of drugs.
They  are  effective  as  analgesics  and  anti-inflamma-
tories for a wide variety of clinical indications, but are
accompanied  by  a  wide  spectrum  of  mechanism-
based side effects. The identification of two isoforms
of cyclooxygenase, COX-1 and COX-2, has led to the
demonstration that COX-1 is constitutively expressed
in most tissues and is homeostatic, and that COX-2
can be induced by a number of stimuli, and is largely
responsible  for  inflammation,  increased  pain,  and
fever. Recent advances by pharmaceutical companies
have  led  to  the  development  of  COX-2-specific
inhibitors, which now command over $6 billion in
annual revenue. The initial hope for these drugs was
the same efficacy as conventional NSAIDs, but with a
better  safety  profile.  However,  recent  results  from
clinical  trials  have  raised  questions  as  to  whether
these drugs are truly safer. One large trial of a COX-
2-specific NSAID has not demonstrated any advantage
over conventional NSAIDs with respect to protection
from clinically significant GI events, while a second
large  trial  of  a  COX-2-specific  NSAID  has  demon-
strated  an  increased  risk  of  myocardial  infarction
compared with a conventional NSAID. In contrast, a
third study has suggested that COX-2-specific inhibi-
tors do not interfere with the cardioprotective effects
of  aspirin.  Additional  COX-2-specific  NSAIDs  are
currently  in  development. Whether  this  subset  of
NSAIDs  proves  to  be  any  safer  than  conventional
NSAIDs awaits the results of further clinical trials.
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